{"generated":"2026-10-12T07:22:54.639Z","patches":[{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-09-19 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04996875","registryValue":"RECRUITING; primary completion 2025-09-19","proposedOn":"2026-10-12"},{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-09-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05208047","registryValue":"RECRUITING; primary completion 2025-09-30","proposedOn":"2026-10-12"},{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06888921","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct04711252","kind":"trial","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","route":"/trials/nct04711252/","field":"enrolled","current":"1370","proposed":"1371","reason":"ClinicalTrials.gov actual enrolment is 1371","source":"https://clinicaltrials.gov/study/NCT04711252","registryValue":"1371 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","route":"/trials/nct01804686/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT01804686","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","route":"/trials/nct01804686/","field":"enrolled","current":"700","proposed":"539","reason":"ClinicalTrials.gov actual enrolment is 539","source":"https://clinicaltrials.gov/study/NCT01804686","registryValue":"539 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06376136","kind":"trial","name":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors","route":"/trials/nct06376136/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06376136","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","route":"/trials/nct06568692/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-07-29 has passed (actual) and the registry status is TERMINATED","source":"https://clinicaltrials.gov/study/NCT06568692","registryValue":"TERMINATED; primary completion 2026-07-29","proposedOn":"2026-10-12"},{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","route":"/trials/nct06568692/","field":"enrolled","current":"90","proposed":"20","reason":"ClinicalTrials.gov actual enrolment is 20","source":"https://clinicaltrials.gov/study/NCT06568692","registryValue":"20 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06929624","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","field":"enrolled","current":"280","proposed":"282","reason":"ClinicalTrials.gov actual enrolment is 282","source":"https://clinicaltrials.gov/study/NCT06929624","registryValue":"282 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06906471","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","field":"phase","current":"3","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT06614192","registryValue":"PHASE2","proposedOn":"2026-10-12"},{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06498986","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/","field":"enrolled","current":"40","proposed":"76","reason":"ClinicalTrials.gov actual enrolment is 76","source":"https://clinicaltrials.gov/study/NCT06498986","registryValue":"76 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07729956","kind":"trial","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","route":"/trials/nct07729956/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07729956","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"nct05667506","kind":"trial","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","route":"/trials/nct05667506/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-05-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05667506","registryValue":"RECRUITING; primary completion 2025-05-30","proposedOn":"2026-10-12"},{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-05-12 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06703398","registryValue":"RECRUITING; primary completion 2026-05-12","proposedOn":"2026-10-12"},{"id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","route":"/trials/nct07678593/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07678593","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT07266441","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","field":"enrolled","current":"157","proposed":"168","reason":"ClinicalTrials.gov actual enrolment is 168","source":"https://clinicaltrials.gov/study/NCT07266441","registryValue":"168 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05023980","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05023980/","field":"enrolled","current":"309","proposed":"282","reason":"ClinicalTrials.gov actual enrolment is 282","source":"https://clinicaltrials.gov/study/NCT05023980","registryValue":"282 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct03812874","kind":"trial","name":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","route":"/trials/nct03812874/","field":"status","current":"recruiting","proposed":"withdrawn","reason":"ClinicalTrials.gov overall status is WITHDRAWN (Due to business considerations and challenges in participant recruitment, the Sponsor has decided to)","source":"https://clinicaltrials.gov/study/NCT03812874","registryValue":"WITHDRAWN","proposedOn":"2026-10-12"},{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT07183189","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","field":"enrolled","current":"576","proposed":"582","reason":"ClinicalTrials.gov actual enrolment is 582","source":"https://clinicaltrials.gov/study/NCT07183189","registryValue":"582 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06833008","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","field":"enrolled","current":"85","proposed":"42","reason":"ClinicalTrials.gov actual enrolment is 42","source":"https://clinicaltrials.gov/study/NCT06833008","registryValue":"42 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","field":"enrolled","current":"660","proposed":"89","reason":"ClinicalTrials.gov actual enrolment is 89","source":"https://clinicaltrials.gov/study/NCT06109272","registryValue":"89 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","field":"phase","current":"1/2","proposed":"1","reason":"ClinicalTrials.gov lists phases PHASE1","source":"https://clinicaltrials.gov/study/NCT06399757","registryValue":"PHASE1","proposedOn":"2026-10-12"},{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","field":"enrolled","current":"100","proposed":"27","reason":"ClinicalTrials.gov actual enrolment is 27","source":"https://clinicaltrials.gov/study/NCT06399757","registryValue":"27 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05020236","kind":"trial","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-02-26 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05020236","registryValue":"RECRUITING; primary completion 2026-02-26","proposedOn":"2026-10-12"},{"id":"nct04495296","kind":"trial","name":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04495296/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT04495296","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","field":"enrolled","current":"410","proposed":"324","reason":"ClinicalTrials.gov actual enrolment is 324","source":"https://clinicaltrials.gov/study/NCT00262769","registryValue":"324 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","route":"/trials/nct03897543/","field":"status","current":"recruiting","proposed":"completed","reason":"ClinicalTrials.gov overall status is COMPLETED","source":"https://clinicaltrials.gov/study/NCT03897543","registryValue":"COMPLETED","proposedOn":"2026-10-12"},{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","route":"/trials/nct03897543/","field":"enrolled","current":"48","proposed":"10","reason":"ClinicalTrials.gov actual enrolment is 10","source":"https://clinicaltrials.gov/study/NCT03897543","registryValue":"10 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","field":"enrolled","current":"891","proposed":"605","reason":"ClinicalTrials.gov actual enrolment is 605","source":"https://clinicaltrials.gov/study/NCT00003855","registryValue":"605 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05477576","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"enrolled","current":"179","proposed":"180","reason":"ClinicalTrials.gov actual enrolment is 180","source":"https://clinicaltrials.gov/study/NCT02196961","registryValue":"180 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","field":"enrolled","current":"635","proposed":"630","reason":"ClinicalTrials.gov actual enrolment is 630","source":"https://clinicaltrials.gov/study/NCT01578655","registryValue":"630 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05932212","kind":"trial","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","route":"/trials/nct05932212/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-05-31 has passed (actual) and the registry status is TERMINATED","source":"https://clinicaltrials.gov/study/NCT05932212","registryValue":"TERMINATED; primary completion 2026-05-31","proposedOn":"2026-10-12"},{"id":"calgb-50303","kind":"trial","name":"Alliance/CALGB 50303","route":"/trials/calgb-50303/","field":"enrolled","current":"491","proposed":"524","reason":"ClinicalTrials.gov actual enrolment is 524","source":"https://clinicaltrials.gov/study/NCT00118209","registryValue":"524 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"enrolled","current":"1425","proposed":"4813","reason":"ClinicalTrials.gov actual enrolment is 4813","source":"https://clinicaltrials.gov/study/NCT00014612","registryValue":"4813 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","field":"enrolled","current":"867","proposed":"984","reason":"ClinicalTrials.gov actual enrolment is 984","source":"https://clinicaltrials.gov/study/NCT03836261","registryValue":"984 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","field":"enrolled","current":"4805","proposed":"4804","reason":"ClinicalTrials.gov actual enrolment is 4804","source":"https://clinicaltrials.gov/study/NCT01358877","registryValue":"4804 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07160686","kind":"trial","name":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","route":"/trials/nct07160686/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07160686","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","field":"enrolled","current":"38","proposed":"953","reason":"ClinicalTrials.gov actual enrolment is 953","source":"https://clinicaltrials.gov/study/NCT02438007","registryValue":"953 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","field":"enrolled","current":"558","proposed":"623","reason":"ClinicalTrials.gov actual enrolment is 623","source":"https://clinicaltrials.gov/study/NCT05382299","registryValue":"623 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"enrolled","current":"401","proposed":"233","reason":"ClinicalTrials.gov actual enrolment is 233","source":"https://clinicaltrials.gov/study/NCT01843062","registryValue":"233 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","field":"enrolled","current":"419","proposed":"421","reason":"ClinicalTrials.gov actual enrolment is 421","source":"https://clinicaltrials.gov/study/NCT02151981","registryValue":"421 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct00722228","kind":"trial","name":"Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","route":"/trials/nct00722228/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-03 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT00722228","registryValue":"RECRUITING; primary completion 2025-03","proposedOn":"2026-10-12"},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"enrolled","current":"665","proposed":"702","reason":"ClinicalTrials.gov actual enrolment is 702","source":"https://clinicaltrials.gov/study/NCT02928224","registryValue":"702 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","field":"enrolled","current":"20176","proposed":"26758","reason":"ClinicalTrials.gov actual enrolment is 26758","source":"https://clinicaltrials.gov/study/NCT04144738","registryValue":"26758 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","field":"enrolled","current":"3181","proposed":"3177","reason":"ClinicalTrials.gov actual enrolment is 3177","source":"https://clinicaltrials.gov/study/NCT02750826","registryValue":"3177 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","field":"enrolled","current":"153","proposed":"220","reason":"ClinicalTrials.gov actual enrolment is 220","source":"https://clinicaltrials.gov/study/NCT02360579","registryValue":"220 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","field":"enrolled","current":"799","proposed":"988","reason":"ClinicalTrials.gov actual enrolment is 988","source":"https://clinicaltrials.gov/study/NCT00861614","registryValue":"988 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06787339","kind":"trial","name":"Capecitabine in Low Risk Triple Negative Breast Cancer","route":"/trials/nct06787339/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06787339","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","field":"enrolled","current":"708","proposed":"818","reason":"ClinicalTrials.gov actual enrolment is 818","source":"https://clinicaltrials.gov/study/NCT04305496","registryValue":"818 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"phase","current":"3","proposed":"4","reason":"ClinicalTrials.gov lists phases PHASE4","source":"https://clinicaltrials.gov/study/NCT02485691","registryValue":"PHASE4","proposedOn":"2026-10-12"},{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","field":"enrolled","current":"97","proposed":"126","reason":"ClinicalTrials.gov actual enrolment is 126","source":"https://clinicaltrials.gov/study/NCT03548207","registryValue":"126 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","field":"enrolled","current":"805","proposed":"987","reason":"ClinicalTrials.gov actual enrolment is 987","source":"https://clinicaltrials.gov/study/NCT03043872","registryValue":"987 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","field":"enrolled","current":"369","proposed":"529","reason":"ClinicalTrials.gov actual enrolment is 529","source":"https://clinicaltrials.gov/study/NCT02017717","registryValue":"529 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","field":"enrolled","current":"243","proposed":"294","reason":"ClinicalTrials.gov actual enrolment is 294","source":"https://clinicaltrials.gov/study/NCT02181738","registryValue":"294 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","field":"enrolled","current":"1581","proposed":"2031","reason":"ClinicalTrials.gov actual enrolment is 2031","source":"https://clinicaltrials.gov/study/NCT02872116","registryValue":"2031 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","field":"enrolled","current":"358","proposed":"505","reason":"ClinicalTrials.gov actual enrolment is 505","source":"https://clinicaltrials.gov/study/NCT02998528","registryValue":"505 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/","field":"enrolled","current":"27","proposed":"32","reason":"ClinicalTrials.gov actual enrolment is 32","source":"https://clinicaltrials.gov/study/NCT03227926","registryValue":"32 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","field":"enrolled","current":"204","proposed":"264","reason":"ClinicalTrials.gov actual enrolment is 264","source":"https://clinicaltrials.gov/study/NCT00353496","registryValue":"264 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct04684147","kind":"trial","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct04684147/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2022-09-22 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04684147","registryValue":"RECRUITING; primary completion 2022-09-22","proposedOn":"2026-10-12"},{"id":"nct06422936","kind":"trial","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct06422936/","field":"enrolled","current":"60","proposed":"50","reason":"ClinicalTrials.gov actual enrolment is 50","source":"https://clinicaltrials.gov/study/NCT06422936","registryValue":"50 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"enrolled","current":"38","proposed":"713","reason":"ClinicalTrials.gov actual enrolment is 713","source":"https://clinicaltrials.gov/study/NCT03600883","registryValue":"713 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","field":"enrolled","current":"226","proposed":"1449","reason":"ClinicalTrials.gov actual enrolment is 1449","source":"https://clinicaltrials.gov/study/NCT00026312","registryValue":"1449 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","field":"enrolled","current":"577","proposed":"921","reason":"ClinicalTrials.gov actual enrolment is 921","source":"https://clinicaltrials.gov/study/NCT01909453","registryValue":"921 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05927142","kind":"trial","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","route":"/trials/nct05927142/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05927142","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"crossfire","kind":"trial","name":"CROSSFIRE","route":"/trials/crossfire/","field":"enrolled","current":"68","proposed":"74","reason":"ClinicalTrials.gov actual enrolment is 74","source":"https://clinicaltrials.gov/study/NCT02791503","registryValue":"74 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"enrolled","current":"1198","proposed":"1221","reason":"ClinicalTrials.gov actual enrolment is 1221","source":"https://clinicaltrials.gov/study/NCT00154102","registryValue":"1221 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","field":"enrolled","current":"355","proposed":"362","reason":"ClinicalTrials.gov actual enrolment is 362","source":"https://clinicaltrials.gov/study/NCT02175212","registryValue":"362 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","route":"/trials/nct07705919/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07705919","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","field":"enrolled","current":"9989","proposed":"12776","reason":"ClinicalTrials.gov actual enrolment is 12776","source":"https://clinicaltrials.gov/study/NCT01397747","registryValue":"12776 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06778382","kind":"trial","name":"Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.","route":"/trials/nct06778382/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-11-01 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06778382","registryValue":"RECRUITING; primary completion 2025-11-01","proposedOn":"2026-10-12"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"enrolled","current":"267","proposed":"477","reason":"ClinicalTrials.gov actual enrolment is 477","source":"https://clinicaltrials.gov/study/NCT04482309","registryValue":"477 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05640791","kind":"trial","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","route":"/trials/nct05640791/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2023-12-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05640791","registryValue":"RECRUITING; primary completion 2023-12-31","proposedOn":"2026-10-12"},{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-01-15 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04844866","registryValue":"RECRUITING; primary completion 2025-01-15","proposedOn":"2026-10-12"},{"id":"nct06050122","kind":"trial","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","route":"/trials/nct06050122/","field":"enrolled","current":"140","proposed":"113","reason":"ClinicalTrials.gov actual enrolment is 113","source":"https://clinicaltrials.gov/study/NCT06050122","registryValue":"113 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"elara","kind":"trial","name":"ELARA","route":"/trials/elara/","field":"enrolled","current":"97","proposed":"98","reason":"ClinicalTrials.gov actual enrolment is 98","source":"https://clinicaltrials.gov/study/NCT03568461","registryValue":"98 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","field":"enrolled","current":"79","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT02435849","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","field":"enrolled","current":"616","proposed":"724","reason":"ClinicalTrials.gov actual enrolment is 724","source":"https://clinicaltrials.gov/study/NCT03778957","registryValue":"724 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","field":"enrolled","current":"594","proposed":"896","reason":"ClinicalTrials.gov actual enrolment is 896","source":"https://clinicaltrials.gov/study/NCT00554229","registryValue":"896 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","field":"enrolled","current":"477","proposed":"709","reason":"ClinicalTrials.gov actual enrolment is 709","source":"https://clinicaltrials.gov/study/NCT00182819","registryValue":"709 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/","field":"enrolled","current":"1925","proposed":"1952","reason":"ClinicalTrials.gov actual enrolment is 1952","source":"https://clinicaltrials.gov/study/NCT00433433","registryValue":"1952 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","field":"enrolled","current":"552","proposed":"483","reason":"ClinicalTrials.gov actual enrolment is 483","source":"https://clinicaltrials.gov/study/NCT04628494","registryValue":"483 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","field":"enrolled","current":"157","proposed":"666","reason":"ClinicalTrials.gov actual enrolment is 666","source":"https://clinicaltrials.gov/study/NCT03625037","registryValue":"666 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"enrolled","current":"178","proposed":"49","reason":"ClinicalTrials.gov actual enrolment is 49","source":"https://clinicaltrials.gov/study/NCT00287105","registryValue":"49 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"enrolled","current":"2260","proposed":"1334","reason":"ClinicalTrials.gov actual enrolment is 1334","source":"https://clinicaltrials.gov/study/NCT00134030","registryValue":"1334 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","field":"enrolled","current":"344","proposed":"595","reason":"ClinicalTrials.gov actual enrolment is 595","source":"https://clinicaltrials.gov/study/NCT03924895","registryValue":"595 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05482516","kind":"trial","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","route":"/trials/nct05482516/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05482516","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct05482516","kind":"trial","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","route":"/trials/nct05482516/","field":"enrolled","current":"20","proposed":"11","reason":"ClinicalTrials.gov actual enrolment is 11","source":"https://clinicaltrials.gov/study/NCT05482516","registryValue":"11 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07670312","kind":"trial","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","route":"/trials/nct07670312/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07670312","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","field":"enrolled","current":"320","proposed":"373","reason":"ClinicalTrials.gov actual enrolment is 373","source":"https://clinicaltrials.gov/study/NCT05306340","registryValue":"373 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05647122","kind":"trial","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/","field":"enrolled","current":"167","proposed":"190","reason":"ClinicalTrials.gov actual enrolment is 190","source":"https://clinicaltrials.gov/study/NCT05647122","registryValue":"190 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","route":"/trials/nct07299409/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07299409","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"enrolled","current":"556","proposed":"674","reason":"ClinicalTrials.gov actual enrolment is 674","source":"https://clinicaltrials.gov/study/NCT02296125","registryValue":"674 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","field":"enrolled","current":"548","proposed":"614","reason":"ClinicalTrials.gov actual enrolment is 614","source":"https://clinicaltrials.gov/study/NCT00310167","registryValue":"614 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06484153","kind":"trial","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","route":"/trials/nct06484153/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-07-22 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06484153","registryValue":"RECRUITING; primary completion 2026-07-22","proposedOn":"2026-10-12"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/","field":"enrolled","current":"1945","proposed":"1500","reason":"ClinicalTrials.gov actual enrolment is 1500","source":"https://clinicaltrials.gov/study/NCT00515554","registryValue":"1500 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct03364530","kind":"trial","name":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","route":"/trials/nct03364530/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-10-21 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT03364530","registryValue":"RECRUITING; primary completion 2025-10-21","proposedOn":"2026-10-12"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"enrolled","current":"930","proposed":"1134","reason":"ClinicalTrials.gov actual enrolment is 1134","source":"https://clinicaltrials.gov/study/NCT03085095","registryValue":"1134 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","field":"enrolled","current":"1171","proposed":"1324","reason":"ClinicalTrials.gov actual enrolment is 1324","source":"https://clinicaltrials.gov/study/NCT03298451","registryValue":"1324 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06435260","kind":"trial","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06435260/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-06-01 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06435260","registryValue":"RECRUITING; primary completion 2025-06-01","proposedOn":"2026-10-12"},{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","field":"enrolled","current":"64","proposed":"103","reason":"ClinicalTrials.gov actual enrolment is 103","source":"https://clinicaltrials.gov/study/NCT03967223","registryValue":"103 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"enrolled","current":"501","proposed":"558","reason":"ClinicalTrials.gov actual enrolment is 558","source":"https://clinicaltrials.gov/study/NCT03434379","registryValue":"558 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","field":"enrolled","current":"483","proposed":"660","reason":"ClinicalTrials.gov actual enrolment is 660","source":"https://clinicaltrials.gov/study/NCT05091567","registryValue":"660 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","field":"enrolled","current":"117","proposed":"136","reason":"ClinicalTrials.gov actual enrolment is 136","source":"https://clinicaltrials.gov/study/NCT05396885","registryValue":"136 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2023-11-22 has passed (actual) and the registry status is UNKNOWN","source":"https://clinicaltrials.gov/study/NCT05027776","registryValue":"UNKNOWN; primary completion 2023-11-22","proposedOn":"2026-10-12"},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","field":"enrolled","current":"403","proposed":"503","reason":"ClinicalTrials.gov actual enrolment is 503","source":"https://clinicaltrials.gov/study/NCT02763579","registryValue":"503 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","field":"enrolled","current":"5502","proposed":"5505","reason":"ClinicalTrials.gov actual enrolment is 5505","source":"https://clinicaltrials.gov/study/NCT02466737","registryValue":"5505 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","route":"/trials/nct03257033/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT03257033","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","field":"enrolled","current":"255","proposed":"579","reason":"ClinicalTrials.gov actual enrolment is 579","source":"https://clinicaltrials.gov/study/NCT03337724","registryValue":"579 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","field":"enrolled","current":"287","proposed":"550","reason":"ClinicalTrials.gov actual enrolment is 550","source":"https://clinicaltrials.gov/study/NCT01710176","registryValue":"550 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","field":"enrolled","current":"75422","proposed":"80761","reason":"ClinicalTrials.gov actual enrolment is 80761","source":"https://clinicaltrials.gov/study/NCT03327597","registryValue":"80761 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","field":"enrolled","current":"53","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT02576990","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","route":"/trials/liger-hn1/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06525220","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"enrolled","current":"102","proposed":"121","reason":"ClinicalTrials.gov actual enrolment is 121","source":"https://clinicaltrials.gov/study/NCT03975907","registryValue":"121 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","field":"enrolled","current":"105","proposed":"345","reason":"ClinicalTrials.gov actual enrolment is 345","source":"https://clinicaltrials.gov/study/NCT02454972","registryValue":"345 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"lyma","kind":"trial","name":"LyMa","route":"/trials/lyma/","field":"enrolled","current":"240","proposed":"299","reason":"ClinicalTrials.gov actual enrolment is 299","source":"https://clinicaltrials.gov/study/NCT00921414","registryValue":"299 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","field":"enrolled","current":"123","proposed":"187","reason":"ClinicalTrials.gov actual enrolment is 187","source":"https://clinicaltrials.gov/study/NCT04649359","registryValue":"187 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","field":"enrolled","current":"423","proposed":"765","reason":"ClinicalTrials.gov actual enrolment is 765","source":"https://clinicaltrials.gov/study/NCT03748641","registryValue":"765 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","field":"phase","current":"1/2","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT04557098","registryValue":"PHASE2","proposedOn":"2026-10-12"},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","field":"enrolled","current":"165","proposed":"194","reason":"ClinicalTrials.gov actual enrolment is 194","source":"https://clinicaltrials.gov/study/NCT04557098","registryValue":"194 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06349590","kind":"trial","name":"Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery","route":"/trials/nct06349590/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-04-06 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06349590","registryValue":"RECRUITING; primary completion 2026-04-06","proposedOn":"2026-10-12"},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","field":"enrolled","current":"105934","proposed":"100000","reason":"ClinicalTrials.gov actual enrolment is 100000","source":"https://clinicaltrials.gov/study/NCT04838756","registryValue":"100000 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct04084496","kind":"trial","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","route":"/trials/nct04084496/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-12-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04084496","registryValue":"RECRUITING; primary completion 2024-12-31","proposedOn":"2026-10-12"},{"id":"nct04110301","kind":"trial","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-01-09 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04110301","registryValue":"RECRUITING; primary completion 2024-01-09","proposedOn":"2026-10-12"},{"id":"nct07723482","kind":"trial","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","route":"/trials/nct07723482/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07723482","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"enrolled","current":"133","proposed":"134","reason":"ClinicalTrials.gov actual enrolment is 134","source":"https://clinicaltrials.gov/study/NCT00402038","registryValue":"134 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-09-11 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06514508","registryValue":"RECRUITING; primary completion 2026-09-11","proposedOn":"2026-10-12"},{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","field":"phase","current":"1/2","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT04634552","registryValue":"PHASE2","proposedOn":"2026-10-12"},{"id":"nct04605913","kind":"trial","name":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","route":"/trials/nct04605913/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT04605913","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"enrolled","current":"142250","proposed":"142318","reason":"ClinicalTrials.gov actual enrolment is 142318","source":"https://clinicaltrials.gov/study/NCT05611632","registryValue":"142318 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06343116","kind":"trial","name":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","route":"/trials/nct06343116/","field":"status","current":"planned","proposed":"withdrawn","reason":"ClinicalTrials.gov overall status is WITHDRAWN (Study withdrawn before enrollment of any participant due to a corporate strategic decision. Not rela)","source":"https://clinicaltrials.gov/study/NCT06343116","registryValue":"WITHDRAWN","proposedOn":"2026-10-12"},{"id":"nct05972655","kind":"trial","name":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","route":"/trials/nct05972655/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-08-20 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05972655","registryValue":"RECRUITING; primary completion 2024-08-20","proposedOn":"2026-10-12"},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","field":"enrolled","current":"84585","proposed":"95000","reason":"ClinicalTrials.gov actual enrolment is 95000","source":"https://clinicaltrials.gov/study/NCT00883792","registryValue":"95000 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"phase","current":"2","proposed":"2/3","reason":"ClinicalTrials.gov lists phases PHASE2, PHASE3","source":"https://clinicaltrials.gov/study/NCT02919787","registryValue":"PHASE2/PHASE3","proposedOn":"2026-10-12"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"enrolled","current":"1836","proposed":"1837","reason":"ClinicalTrials.gov actual enrolment is 1837","source":"https://clinicaltrials.gov/study/NCT02032823","registryValue":"1837 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06736717","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","field":"enrolled","current":"21","proposed":"16","reason":"ClinicalTrials.gov actual enrolment is 16","source":"https://clinicaltrials.gov/study/NCT06736717","registryValue":"16 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"enrolled","current":"54","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT02680587","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"enrolled","current":"140","proposed":"71","reason":"ClinicalTrials.gov actual enrolment is 71","source":"https://clinicaltrials.gov/study/NCT02423603","registryValue":"71 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"enrolled","current":"450","proposed":"454","reason":"ClinicalTrials.gov actual enrolment is 454","source":"https://clinicaltrials.gov/study/NCT01617161","registryValue":"454 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"phase","current":"2/3","proposed":"3","reason":"ClinicalTrials.gov lists phases PHASE3","source":"https://clinicaltrials.gov/study/NCT00303784","registryValue":"PHASE3","proposedOn":"2026-10-12"},{"id":"pathos","kind":"trial","name":"PATHOS","route":"/trials/pathos/","field":"phase","current":"2/3","proposed":"3","reason":"ClinicalTrials.gov lists phases PHASE3","source":"https://clinicaltrials.gov/study/NCT02215265","registryValue":"PHASE3","proposedOn":"2026-10-12"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"enrolled","current":"18644","proposed":"18729","reason":"ClinicalTrials.gov actual enrolment is 18729","source":"https://clinicaltrials.gov/study/NCT00122681","registryValue":"18729 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06788912","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","route":"/trials/nct06788912/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06788912","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","field":"phase","current":"3","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT06960577","registryValue":"PHASE2","proposedOn":"2026-10-12"},{"id":"nct05326243","kind":"trial","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","route":"/trials/nct05326243/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05326243","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct07509008","kind":"trial","name":"Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum","route":"/trials/nct07509008/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07509008","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-03-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04643418","registryValue":"RECRUITING; primary completion 2025-03-31","proposedOn":"2026-10-12"},{"id":"nct05103358","kind":"trial","name":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","route":"/trials/nct05103358/","field":"enrolled","current":"120","proposed":"128","reason":"ClinicalTrials.gov actual enrolment is 128","source":"https://clinicaltrials.gov/study/NCT05103358","registryValue":"128 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05864534","kind":"trial","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","route":"/trials/nct05864534/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05864534","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct04586478","kind":"trial","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct04586478/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-03-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04586478","registryValue":"RECRUITING; primary completion 2024-03-30","proposedOn":"2026-10-12"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"enrolled","current":"101","proposed":"107","reason":"ClinicalTrials.gov actual enrolment is 107","source":"https://clinicaltrials.gov/study/NCT03599713","registryValue":"107 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"polargo","kind":"trial","name":"POLARGO","route":"/trials/polargo/","field":"enrolled","current":"255","proposed":"270","reason":"ClinicalTrials.gov actual enrolment is 270","source":"https://clinicaltrials.gov/study/NCT04182204","registryValue":"270 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"enrolled","current":"879","proposed":"1000","reason":"ClinicalTrials.gov actual enrolment is 1000","source":"https://clinicaltrials.gov/study/NCT03274492","registryValue":"1000 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct04495088","kind":"trial","name":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04495088/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-07-31 has passed (actual) and the registry status is TERMINATED","source":"https://clinicaltrials.gov/study/NCT04495088","registryValue":"TERMINATED; primary completion 2026-07-31","proposedOn":"2026-10-12"},{"id":"nct04495088","kind":"trial","name":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04495088/","field":"enrolled","current":"550","proposed":"215","reason":"ClinicalTrials.gov actual enrolment is 215","source":"https://clinicaltrials.gov/study/NCT04495088","registryValue":"215 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07271355","kind":"trial","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","route":"/trials/nct07271355/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07271355","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/","field":"enrolled","current":"1018","proposed":"1217","reason":"ClinicalTrials.gov actual enrolment is 1217","source":"https://clinicaltrials.gov/study/NCT00140582","registryValue":"1217 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/","field":"enrolled","current":"480","proposed":"472","reason":"ClinicalTrials.gov actual enrolment is 472","source":"https://clinicaltrials.gov/study/NCT03478488","registryValue":"472 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","field":"enrolled","current":"796","proposed":"895","reason":"ClinicalTrials.gov actual enrolment is 895","source":"https://clinicaltrials.gov/study/NCT03732820","registryValue":"895 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"enrolled","current":"1643","proposed":"82849","reason":"ClinicalTrials.gov actual enrolment is 82849","source":"https://clinicaltrials.gov/study/NCT02044172","registryValue":"82849 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"enrolled","current":"764","proposed":"400","reason":"ClinicalTrials.gov actual enrolment is 400","source":"https://clinicaltrials.gov/study/NCT03368547","registryValue":"400 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"enrolled","current":"1144","proposed":"1140","reason":"ClinicalTrials.gov actual enrolment is 1140","source":"https://clinicaltrials.gov/study/NCT04720157","registryValue":"1140 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06788171","kind":"trial","name":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","route":"/trials/nct06788171/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06788171","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/","field":"enrolled","current":"1522","proposed":"1930","reason":"ClinicalTrials.gov actual enrolment is 1930","source":"https://clinicaltrials.gov/study/NCT00744497","registryValue":"1930 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT07468071","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","field":"enrolled","current":"40","proposed":"25","reason":"ClinicalTrials.gov actual enrolment is 25","source":"https://clinicaltrials.gov/study/NCT07468071","registryValue":"25 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"rtog-0415","kind":"trial","name":"RTOG 0415","route":"/trials/rtog-0415/","field":"enrolled","current":"1115","proposed":"1116","reason":"ClinicalTrials.gov actual enrolment is 1116","source":"https://clinicaltrials.gov/study/NCT00331773","registryValue":"1116 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","field":"enrolled","current":"1979","proposed":"2028","reason":"ClinicalTrials.gov actual enrolment is 2028","source":"https://clinicaltrials.gov/study/NCT00002597","registryValue":"2028 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","field":"enrolled","current":"291","proposed":"299","reason":"ClinicalTrials.gov actual enrolment is 299","source":"https://clinicaltrials.gov/study/NCT00002569","registryValue":"299 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","field":"enrolled","current":"760","proposed":"840","reason":"ClinicalTrials.gov actual enrolment is 840","source":"https://clinicaltrials.gov/study/NCT00002874","registryValue":"840 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","field":"enrolled","current":"309","proposed":"776","reason":"ClinicalTrials.gov actual enrolment is 776","source":"https://clinicaltrials.gov/study/NCT05953181","registryValue":"776 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"enrolled","current":"55581","proposed":"55579","reason":"ClinicalTrials.gov actual enrolment is 55579","source":"https://clinicaltrials.gov/study/NCT04778670","registryValue":"55579 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct07448077","kind":"trial","name":"Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC","route":"/trials/nct07448077/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-03-01 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07448077","registryValue":"RECRUITING; primary completion 2026-03-01","proposedOn":"2026-10-12"},{"id":"nct07469306","kind":"trial","name":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","route":"/trials/nct07469306/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07469306","registryValue":"RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06050317","kind":"trial","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","route":"/trials/nct06050317/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-08-18 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06050317","registryValue":"RECRUITING; primary completion 2025-08-18","proposedOn":"2026-10-12"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"enrolled","current":"391","proposed":"450","reason":"ClinicalTrials.gov actual enrolment is 450","source":"https://clinicaltrials.gov/study/NCT01844986","registryValue":"450 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06754085","kind":"trial","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","field":"status","current":"recruiting","proposed":"completed","reason":"ClinicalTrials.gov overall status is COMPLETED","source":"https://clinicaltrials.gov/study/NCT06754085","registryValue":"COMPLETED","proposedOn":"2026-10-12"},{"id":"nct04494503","kind":"trial","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-10-20 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04494503","registryValue":"RECRUITING; primary completion 2024-10-20","proposedOn":"2026-10-12"},{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-07-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06297226","registryValue":"RECRUITING; primary completion 2026-07-31","proposedOn":"2026-10-12"},{"id":"nct03874026","kind":"trial","name":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","route":"/trials/nct03874026/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2023-05-19 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT03874026","registryValue":"RECRUITING; primary completion 2023-05-19","proposedOn":"2026-10-12"},{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT04145622","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","field":"enrolled","current":"250","proposed":"247","reason":"ClinicalTrials.gov actual enrolment is 247","source":"https://clinicaltrials.gov/study/NCT04145622","registryValue":"247 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","field":"enrolled","current":"255","proposed":"259","reason":"ClinicalTrials.gov actual enrolment is 259","source":"https://clinicaltrials.gov/study/NCT01872260","registryValue":"259 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","field":"phase","current":"1/2","proposed":"1","reason":"ClinicalTrials.gov lists phases PHASE1","source":"https://clinicaltrials.gov/study/NCT05673057","registryValue":"PHASE1","proposedOn":"2026-10-12"},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","field":"enrolled","current":"249","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT05673057","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","route":"/trials/nct06596694/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06596694","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","field":"enrolled","current":"530","proposed":"584","reason":"ClinicalTrials.gov actual enrolment is 584","source":"https://clinicaltrials.gov/study/NCT06619236","registryValue":"584 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-10-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06909877","registryValue":"RECRUITING; primary completion 2025-10-31","proposedOn":"2026-10-12"},{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/","field":"enrolled","current":"400","proposed":"393","reason":"ClinicalTrials.gov actual enrolment is 393","source":"https://clinicaltrials.gov/study/NCT04626479","registryValue":"393 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/","field":"enrolled","current":"370","proposed":"263","reason":"ClinicalTrials.gov actual enrolment is 263","source":"https://clinicaltrials.gov/study/NCT04626518","registryValue":"263 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"summit-lung","kind":"trial","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","field":"enrolled","current":"12773","proposed":"13035","reason":"ClinicalTrials.gov actual enrolment is 13035","source":"https://clinicaltrials.gov/study/NCT03934866","registryValue":"13035 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05218889","kind":"trial","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-12-16 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05218889","registryValue":"RECRUITING; primary completion 2024-12-16","proposedOn":"2026-10-12"},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","field":"enrolled","current":"1535","proposed":"3040","reason":"ClinicalTrials.gov actual enrolment is 3040","source":"https://clinicaltrials.gov/study/NCT00002651","registryValue":"3040 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","field":"enrolled","current":"994","proposed":"1038","reason":"ClinicalTrials.gov actual enrolment is 1038","source":"https://clinicaltrials.gov/study/NCT00134056","registryValue":"1038 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","field":"enrolled","current":"805","proposed":"1054","reason":"ClinicalTrials.gov actual enrolment is 1054","source":"https://clinicaltrials.gov/study/NCT03395197","registryValue":"1054 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"enrolled","current":"2298","proposed":"3451","reason":"ClinicalTrials.gov actual enrolment is 3451","source":"https://clinicaltrials.gov/study/NCT00983684","registryValue":"3451 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05343013","kind":"trial","name":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","route":"/trials/nct05343013/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05343013","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"nct05343013","kind":"trial","name":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","route":"/trials/nct05343013/","field":"enrolled","current":"25","proposed":"30","reason":"ClinicalTrials.gov actual enrolment is 30","source":"https://clinicaltrials.gov/study/NCT05343013","registryValue":"30 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct04214262","kind":"trial","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","route":"/trials/nct04214262/","field":"enrolled","current":"415","proposed":"417","reason":"ClinicalTrials.gov actual enrolment is 417","source":"https://clinicaltrials.gov/study/NCT04214262","registryValue":"417 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05555888","kind":"trial","name":"The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer","route":"/trials/nct05555888/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-03-12 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05555888","registryValue":"RECRUITING; primary completion 2024-03-12","proposedOn":"2026-10-12"},{"id":"nct05624138","kind":"trial","name":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","route":"/trials/nct05624138/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-04-04 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05624138","registryValue":"RECRUITING; primary completion 2024-04-04","proposedOn":"2026-10-12"},{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","field":"enrolled","current":"266","proposed":"629","reason":"ClinicalTrials.gov actual enrolment is 629","source":"https://clinicaltrials.gov/study/NCT03390504","registryValue":"629 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06756269","kind":"trial","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","route":"/trials/nct06756269/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-10-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06756269","registryValue":"RECRUITING; primary completion 2025-10-30","proposedOn":"2026-10-12"},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","field":"enrolled","current":"594","proposed":"584","reason":"ClinicalTrials.gov actual enrolment is 584","source":"https://clinicaltrials.gov/study/NCT01041404","registryValue":"584 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"enrolled","current":"685","proposed":"810","reason":"ClinicalTrials.gov actual enrolment is 810","source":"https://clinicaltrials.gov/study/NCT03875235","registryValue":"810 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"tosca","kind":"trial","name":"TOSCA","route":"/trials/tosca/","field":"enrolled","current":"3759","proposed":"3756","reason":"ClinicalTrials.gov actual enrolment is 3756","source":"https://clinicaltrials.gov/study/NCT00646607","registryValue":"3756 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","field":"enrolled","current":"421","proposed":"814","reason":"ClinicalTrials.gov actual enrolment is 814","source":"https://clinicaltrials.gov/study/NCT01888601","registryValue":"814 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","field":"enrolled","current":"438","proposed":"437","reason":"ClinicalTrials.gov actual enrolment is 437","source":"https://clinicaltrials.gov/study/NCT01996267","registryValue":"437 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"enrolled","current":"120","proposed":"143","reason":"ClinicalTrials.gov actual enrolment is 143","source":"https://clinicaltrials.gov/study/NCT05774756","registryValue":"143 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"transcend-nhl-001","kind":"trial","name":"TRANSCEND NHL 001","route":"/trials/transcend-nhl-001/","field":"enrolled","current":"269","proposed":"387","reason":"ClinicalTrials.gov actual enrolment is 387","source":"https://clinicaltrials.gov/study/NCT02631044","registryValue":"387 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct06011109","kind":"trial","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","route":"/trials/nct06011109/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06011109","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-12"},{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","field":"enrolled","current":"508","proposed":"509","reason":"ClinicalTrials.gov actual enrolment is 509","source":"https://clinicaltrials.gov/study/NCT00719797","registryValue":"509 (ACTUAL)","proposedOn":"2026-10-12"},{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-12-15 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05948813","registryValue":"RECRUITING; primary completion 2025-12-15","proposedOn":"2026-10-12"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"enrolled","current":"14","proposed":"17","reason":"ClinicalTrials.gov actual enrolment is 17","source":"https://clinicaltrials.gov/study/NCT02304367","registryValue":"17 (ACTUAL)","proposedOn":"2026-10-12"}]}